RA-ILD: Tracking Function and CT - Takeaways - MDSpire

RA-ILD: Tracking Function and CT

Conventional monitoring markers do not change before deaths in this predominantly mild cohort.

  • By

  • Kathryn Wighton

  • March 6, 2026

  • 4 min

Share

  • 1

    Pulmonary function and CT measures remained stable over 24 months in patients with rheumatoid arthritis-associated interstitial lung disease.

  • 2

    The study involved 105 patients, with 80% showing pulmonary fibrosis, though only 20% were classified as usual interstitial pneumonia.

  • 3

    At 24 months, 12% of patients improved, 69% remained stable, and 19% worsened, with no significant changes in quantitative CT measures.

  • 4

    Eight patients (8%) died during the study, with no preceding decline in FVC or imaging parameters noted prior to death.

  • 5

    The study's findings challenge the conventional understanding of ILD, indicating mortality can occur without prior functional decline.

Original Source(s)

RA-ILD: Tracking Function and CT

  • by Kathryn Wighton

  • March 6, 2026

Related Content

Upadacitinib and Pain in RA, PsA

Mediation analysis suggests direct and indirect effects on pain reduction in rheumatoid and psoriatic arthritis.

Trial Exclusions May Skew RA Drug Comparisons

Nearly 40% of registry patients would have been excluded from phase 3 randomized controlled trials, with exclusion criteria distributed unevenly across drug classes.

RA Prescribing Patterns Shift Over 15 Years

An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.